Quarterly ResultJul 30, 2026, 07:06 AM
Madrigal Q2 Net Sales $364.3M; Rezdiffra Patients Double
AI Summary
Madrigal Pharmaceuticals reported strong second-quarter 2026 financial results, with Rezdiffra net sales reaching $364.3 million, a 71% increase year-over-year. The company also announced that over 49,000 patients were on Rezdiffra by June 30, 2026, more than doubling from the prior year, reflecting robust physician adoption and patient demand. Despite the strong sales, Madrigal reported a net loss of $57.9 million for the quarter, while advancing its pipeline with the initiation of a Phase 1 trial for MGL-2086 and strengthening its intellectual property for Rezdiffra.
Key Highlights
- Second-quarter 2026 Rezdiffra net sales were $364.3 million, a 71% year-over-year growth.
- Over 49,000 patients were on Rezdiffra as of June 30, 2026, more than doubling from Q2 2025.
- Cash, cash equivalents, restricted cash, and marketable securities totaled $838.9 million.
- Net loss for Q2 2026 was $57.9 million, or $1.99 per share.
- Operating expenses for Q2 2026 were $420.6 million, including $35.4 million in stock-based compensation.
- Strengthened IP portfolio with 3 new resmetirom patents, including one for F4c treatment.
- Initiated Phase 1 trial dosing for MGL-2086 (oral GLP-1) as part of a combination program in MASH.
Price Impact
More from MDGL